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Expression of the brown adipocyte-specific gene, uncoupling protein 1 (UCP1), is increased by both PPAR𝛾 stimulation and
cAMP activation through their ability to stimulate the expression of the PPAR coactivator PGC1𝛼. In HIB1B brown preadipocytes,
combination of the PPAR𝛾 agonist, rosiglitazone, and the cAMP stimulator forskolin synergistically increased UCP1 mRNA
expression, but PGC1𝛼 expression was only increased additively by the two drugs. The PPAR𝛾 antagonist, GW9662, and the PKA
inhibitor, H89, both inhibited UCP1 expression stimulated by rosiglitazone and forskolin but PGC1𝛼 expression was not altered to
the same extent. Reporter studies demonstrated that combined rosiglitazone and forskolin synergistically activated transcription
froma full length 3.1 kbpUCP1 luciferase promoter construct, but the responsewas only additive andmuch reducedwhen aminimal
260 bp proximal UCP1 promoter was examined. Rosiglitazone and forskolin in combination were able to synergistically stimulate
promoters comprising of tandem repeats of either PPREs or CREs. We conclude that rosiglitazone and forskolin act together to
synergistically activate the UCP1 promoter directly rather than by increasing PGC1𝛼 expression and by a mechanism involving
cross-talk between the signalling systems regulating the CRE and PPRE on the promoters.
1. Introduction
Nonshivering thermogenesis in brown adipose tissue (BAT)
in response to a cold environment is initiated by sympa-
thetic neural stimulation of 𝛽-adrenergic receptors on brown
adipocytes which elevate intracellular cyclic AMP (cAMP)
and, via the protein kinase A (PKA) pathway, increase the
expression and thermogenic activity of uncoupling protein
1 (UCP1) [1]. UCP1 is BAT specific and responsible for
uncoupling oxidative phosphorylation by enabling protons to
return to the mitochondrial matrix without ATP synthesis,
thereby producing heat. UCP1 expressing BAT has recently
been identified in humans and has been proposed as a target
for activation to increase energy expenditure and prevent or
treat obesity [2].
UCP1 expression has been suggested to be regulated
by the cAMP-inducible peroxisome proliferator activated
coactivator 1𝛼 (PGC1𝛼) which interacts with a BAT deter-
mination factor, PRDM16, to increase the expression of a
number of BAT-selective genes including Cidea [3]. We have
also shown that the cAMP-inducible transcription factor
C/EBP𝛽 stimulates PGC1𝛼 expression in white and brown
adipocytes by binding to the cAMP response element (CRE)
on the PGC1𝛼 proximal promoter [4, 5] while others have
demonstrated that PKA activation of PGC1𝛼 expression
involves phosphorylation of p38 MAPK [6]. The PPAR𝛾
ligand, rosiglitazone increases expression of PGC1𝛼 [7, 8]
acting on a distal PPRE which binds PPAR𝛾/retinoid X
receptor heterodimers and further positively autoregulates
its own expression by coactivating PPAR𝛾 responsiveness to
rosiglitazone [7]. Furthermore, C/EBP𝛽 has been suggested
to bind to PRDM16 to activate PGC1𝛼 expression during
brown adipogenesis [9].
Therefore, UCP1 expression is thought to be regulated
indirectly through an increased expression of PGC1𝛼 which
then coactivates PPAR𝛾 transactivation of the PPRE on
the UCP1 enhancer [6]. cAMP response elements (CREs)
have also been identified in the proximal promoter and a
distal enhancer of UCP1 [6, 10], but the relative roles of
direct and indirect interactions with the UCP1 promoter
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are uncertain. Furthermore, few studies have examined the
interaction between cAMP and PPAR𝛾 ligands. Here, we
report that stimulation of the PKA and PPAR𝛾 signaling
pathways synergistically and directly stimulates transcription
from the UCP1 promoter, due to the cross-talk between the
two pathways.
2. Methods
2.1. Plasmids. The firefly luciferase reporter gene constructs
containing the 3.1 kbp or 260 bp upstream of mouse UCP1
transcription site were kind gifts from Leslie P. Kozak,
Pennington Biomedical Research Center, Louisana [10]. The
2.6 kbp PGC1𝛼-pGL3-Luc containing 2600 bp insert size
between +78 and −2533 with respect to mouse transcript
start site was purchased from Addgene (UK), and the 264 bp
(264 PGC1𝛼-pGL3) from the region upstream of the rodent
Pgc-1𝛼 transcription start site ligated to the pGL3-Basic
vector (Promega) has been described [4]. The CRE positive
vector (4 × CRE-Luc) that contains four repeat copies of
the consensus CRE sequence upstream of a TATA box to
drive expression of the firefly luciferase gene was purchased
from Stratagene. The PPRE positive vector consisting of
mouse PPRE × 3-TK-luc containing 3 direct repeat (DR1)
of response elements (AGGACAAAGGTCA) upstream of
a luciferase gene was purchased from Addgene (UK). The
−2253-CRE-mut-PGC1𝛼-Luc promoter construct was kindly
given by F. Villarroya (University of Barcelona, Barcelona,
Spain). The −2253-CRE-mut-PGC1𝛼-Luc contains a point
mutation at −146/−129 which was obtained by digestion of
−2553-PGC1𝛼-Luc with PvuII and ZraI and further ligation
[7].
2.2. Cell Culture, Transfections, and Luciferase Assays. HIB-
1B cells (kindly provided by B. Spiegelman) were maintained
in DMEM with 10% FBS (Invitrogen) in 5% CO
2
. For
transfections, HIB-1B cells were cultured to 80% confluence
and then were transfected with pGL3 luciferase plasmids
using Fugene 6 (Roche) according to the manufacturer’s
instructions.The pRL-SV40 construct (Promega) that carries
renilla luciferase genewas cotransfected as an internal control
for monitoring the transfection efficiency. Twenty-four hours
later, cells were treated with DMSO (control), rosiglitazone
(10 𝜇M) for 24 hours, or forskolin (10𝜇M) for the final 12
hours of rosiglitazone treatment, in serum-free medium,
before luciferase activity was measured using the Dual-
Luciferase assay kit (Promega), as recommended by the
manufacturer. Values were normalised relative to the renilla
signal to allow for differences in transfection efficiency.
For mRNA expression studies, HIB-1B cells were grown
to confluence and then treated withH89 (10 𝜇M) for 1 hour or
GW9662 (30 𝜇M) for 3 hours prior to and during addition of
rosiglitazone (Rosi) (10 𝜇M) for 24 hours or forskolin (Fosk)
(10 𝜇M) for the final 3 hours of rosiglitazone treatment, before
RNA extraction, as indicated. All drugs were added in serum-
free medium. Controls were treated with DMSO.
2.3. Real-Time PCR. Total RNA was extracted from cultured
cells using TRI reagent (Sigma). Prior to RT-PCR, samples
were treated with RNase-free DNase to remove contaminat-
ing genomic or plasmid DNA. cDNA was generated using
the cDNA synthesis kit from Qiagen. Quantitative real-time
PCR (qRT-PCR) was performed using Sybr green according
to the manufacturer’s instructions (Roche). The sequences
of the primers used for real-time PCR are given in Table 1.
Expression levels for all genes were normalized to expression
of the house keeping gene, 36B4.
2.4. Statistical Analysis. To examine the effects of agonists
(forskolin, rosiglitazone) and antagonists (GW9662, H89) as
well as interaction effects (agonists × antagonists) on mRNA
levels or luciferase reporter activities of all groups, a two-
way ANOVA (SPSS, v17) was performed. The comparisons
between agonist and agonist + antagonist treated cells or
between wildtype 2.6 kb PGC1𝛼-Luc and CRE-mut-PGC1𝛼-
Luc transfected cells were determined by t test.
3. Results
3.1. Synergistic Increase in UCP1, but Not PGC1𝛼, Cidea, or
PRDM16 in Response to Combined Forskolin and Rosiglitazone
Is Inhibited by a PKA Inhibitor (H89) and a PPAR𝛾Antagonist
(GW9662). Addition of forskolin for 3 h and rosiglitazone
for 24 h increased UCP1 mRNA expression by 12-fold (𝑃 <
0.001) and 5.5-fold (𝑃 < 0.001), respectively, but when
forskolin was added during the last 3 h of incubation with
rosiglitazone, a synergistic 40-fold increase (𝑃 < 0.001)
was observed, relative to control confluent HIB1B cells
(Figure 1(a)). Addition of the PKA inhibitorH89 significantly
increased by 4-fold (𝑃 < 0.001) the basal expression of
UCP1mRNAbut completely blocked the stimulatory effect of
forskolin (𝑃 < 0.001) and inhibited the synergistic response
to forskolin plus rosiglitazone by 75% (𝑃 < 0.001). H89
also suppressed theUCP1mRNA response to rosiglitazone by
75% (𝑃 < 0.001). The PPAR𝛾 antagonist GW9662 doubled
the basal levels of UCP1 mRNA but inhibited the response
to forskolin and rosiglitazone by 50–75% (𝑃 < 0.001). A
mixture of GW9662 andH89 decreasedUCP1mRNAby 88%
in response to forskolin plus rosiglitazone, relative to control
cells (𝑃 < 0.001).
In contrast, PGC1𝛼 mRNA was upregulated two-fold by
forskolin or rosiglitazone treatment (𝑃 < 0.001; Figure 1(b))
and only additively by combined forskolin and rosiglita-
zone treatment. Addition of H89 downregulated the PGC1𝛼
expression response to forskolin by 77% (𝑃 < 0.001),
but surprisingly, addition of GW9662 did not alter PGC1𝛼
expression in the presence of forskolin, or rosiglitazone,
separately or in combination. These results suggested that
the action of cAMP and PPAR𝛾 stimulation on the initiation
of UCP1 expression was directly targeting UCP1 rather than
indirectly acting on PGC1𝛼 expression.
We next examined whether the brown selective genes
Cidea and PRDM16 were responsive to PKA and PPAR𝛾
modulation. Similar to UCP1, expression of Cidea was
increased by both forskolin (𝑃 < 0.001) and rosiglitazone
(𝑃 < 0.001) by 8-fold and 18-fold, respectively, and when
forskolin and rosiglitazone were combined together, there
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Table 1: The sequences of primers for the real-time PCR.
Gene Forward primer Reverse primer
PGC1𝛼 TGAGAGACCGCTTTGAAGTTTTT CAGGTGTAACGGTAGGTGATGAAA
PRDM16 TCTTACTTCTCCGAGATCCGAAA GATCTCAGGCCGTTTGTCCAT
C/EBP𝛽 AGCGGCTGCAGAAGAAGGT GGCAGCTGCTTGAACAAGTTC
UCP1 GCCATCTGCATGGGATCAA GGTCGTCCCTTTCCAAAGTG
PPAR𝛾 GTGCCAGTTTCG ATCCGT AGA GGCCAGCATCGTGTAGATA
aP2 AACACCGAGATTTCC ACACATTCCACCACCAG
Cidea ACAGAAATGGACACCGGGTAGT CGAAGGTGACTCTGGCTATTCC
36B4 TCCAGGCTTTGGGCATCA TTATCAGCTGCACATCACTCAGAAT
was a synergistic 40-fold stimulatory effect (𝑃 < 0.001)
relative to control cells (Figure 1(c)). In contrast to UCP1,
although H89 caused a significant 65% reduction (𝑃 <
0.001) in Cidea expression in response to forskolin, there
was no effect of H89 on Cidea expression in response
to rosiglitazone and only a small 25% inhibition of the
response to combined forskolin plus rosiglitazone (𝑃 < 0.01)
was observed. Furthermore, GW9662 did not alter Cidea
expression in response to rosiglitazone or forskolin plus
rosiglitazone although forskolin stimulated Cidea expression
was suppressed by 21% (𝑃 < 0.01). Again in contrast to
UCP1, PRDM16 mRNA levels were induced by only 3-fold
(𝑃 < 0.001) in response to forskolin or rosiglitazone and
only additively in response to forskolin plus rosiglitazone
(𝑃 < 0.001) (Figure 1(d)), relative to control cells. Addition
of H89 did not alter the response to either forskolin or
rosiglitazone, but the response to combined forskolin and
rosiglitazonewas inhibited by 58% (𝑃 < 0.05). Addition of the
PPAR𝛾 antagonist, GW9662, inhibited PRDM16 expression
in response to either forskolin or rosiglitazone by 56–60%
(𝑃 < 0.001), but GW9662 failed to inhibit the PRDM16
response to forskolin and rosiglitazone in combination.
Expression of the adipogenic differentiationmarker gene aP2,
in response to stimulation by forskolin and rosiglitazone,
was similarly less sensitive to H89 and GW9663, compared
to UCP1 (results not shown). These results again suggest
that the action of cAMP and PPAR𝛾 stimulation on the
initiation of UCP1 expression was directly targeting the UCP1
promoter.
3.2. Effect of a PKA Inhibitor (H89) and a PPAR𝛾 Antagonist
(GW9662) on C/EBP𝛽 and PPAR𝛾 Expression in Response to
Forskolin and Rosiglitazone Is Different to Responses Observed
on UCP1. Our attention was then drawn to the effect of
rosiglitazone and forskolin on the expression of C/EBP𝛽
and PPAR𝛾, genes which have been reported to regulate
UCP1 expression. C/EBP𝛽 mRNA was increased by 18-fold
(𝑃 < 0.001) in response to forskolin and 4.5-fold (𝑃 <
0.001) in response to rosiglitazone, relative to control cells
(Figure 1(e)). In addition, a 26-fold additive response to
combined forskolin and rosiglitazone (𝑃 < 0.01) in C/EBP𝛽
mRNA was observed. H89 blocked forskolin stimulated
C/EBP𝛽 expression by 82% (𝑃 < 0.001), rosiglitazone
induced expression by 32% (𝑃 < 0.01), and the combined
effect of forskolin plus rosiglitazone was inhibited by 68%
(𝑃 < 0.001). GW9662 blocked forskolin stimulated C/EBP𝛽
expression by 93% (𝑃 < 0.001), rosiglitazone induced
C/EBP𝛽 expression by 49% (𝑃 < 0.01), and inhibited the
additive activation by forskolin and rosiglitazone combina-
tion on C/EBP𝛽 expression by 50% (𝑃 < 0.001).
PPAR𝛾 mRNA was increased by 5.2-fold (𝑃 < 0.001)
in response to PKA activation with forskolin and 1.7-fold
(𝑃 < 0.05) by rosiglitazone, but there was no further
response when forskolin and rosiglitazone were combined
(Figure 1(f)). Addition of H89 significantly decreased the
response to forskolin by 70% (𝑃 < 0.001). GW9662 reduced
PPAR𝛾 expression by 90% (𝑃 < 0.001) in response to
forskolin and by 73% (𝑃 < 0.001) and 70% (𝑃 < 0.001),
respectively, in response to rosiglitazone and forskolin plus
rosiglitazone, respectively.
Therefore, the expression of PPAR𝛾 and C/EBP𝛽 was
predominantly increased by forskolin with only a small effect
of combining forskolin and rosiglitazone, but these effects
could be suppressed by both PKA inhibition (H89) and the
PPAR𝛾 antagonist GW9662. Combined the results suggest
that the effects of the inhibitors and stimulators on UCP1
expression could not be completely explained by changes
in the expression of regulatory genes measured. Similar
conclusions were drawn when expression levels of CtBP1,
CtBP2, and RIP140 were measured (result not shown).
3.3. Synergistic Activation of UCP1 and PGC1𝛼 Transcription
by Combined Forskolin and Rosiglitazone Requires the Full
Length Promoters. We next examined the effect of PKA and
PPAR𝛾 activation on full length and truncated UCP1 and
PGC1𝛼 promoter luciferase reporter constructs transfected
into confluent HIB1B cells. Addition of rosiglitazone for
24 h or forskolin for 12 h significantly induced transcriptional
activity of the full length 3.1 kb UCP1 promoter reporter
construct by 22-fold and 4.1-fold (𝑃 < 0.001), respectively,
and when the drugs were combined, synergistically increased
transcription by 82-fold (Figure 2(a); 𝑃 < 0.001). By
comparison, transcription from the proximal 260 bp UCP1
promoter was only stimulated 2-fold and 6-fold, by forskolin
and rosiglitazone, respectively (𝑃 < 0.001), and combined
addition of the two drugs increased reporter activity by 10-
fold (𝑃 < 0.001; Figure 2(b)). The 260 bp promoter contains
only one CRE, no PPRE, but is activated by forskolin to
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Figure 1:The effect of forskolin and rosiglitazone on mRNA expression of (a) UCP1, (b) PGC1𝛼, (c) Cidea, (d) PRDM16, (e) C/EBP𝛽, and (f)
PPAR𝛾 is mediated by PKA and PPAR𝛾 dependent pathways. HIB-1B cells were grown to confluence and then treated with H89 (10𝜇M) for
1 hour or GW9662 (30𝜇M) for 3 hours prior to and during addition of rosiglitazone (Rosi) (10 𝜇M) for 24 hours, or forskolin (Fosk) (10𝜇M)
for the final 3 hours of rosiglitazone treatment, before RNA extraction, as indicated. All drugs were added in serum-free medium. Controls
were treated with DMSO. Gene expression levels were analysed by quantitative real-time PCR and normalized against 36B4 expression. Error
bar means the mean ± SEM of triplicate observations within a single experiment performed in triplicate. ∗∗∗ Significant difference 𝑃 < 0.001
with respect to control; ### significant difference 𝑃 < 0.001 due to H89 or GW9662 for each experiment.
approximately the same extent, as the 3.1 kb UCP1 promoter
reporter construct [11].
We next examined a PGC1𝛼-Luc promoter reporter.
Forskolin addition significantly doubled (𝑃 < 0.001) tran-
scription from the full length 2.6 kb PGC1𝛼 promoter while
addition of rosiglitazone stimulated by 12-fold (𝑃 < 0.001;
Figure 2(c)). When forskolin and rosiglitazone were com-
bined together, there was a synergistic 35-fold increase in the
2.6 kb PGC1𝛼 transcription activity (𝑃 < 0.001). As observed
with the proximal UCP1 promoter, there were significant
(𝑃 < 0.001) effects of forskolin and rosiglitazone, alone or
in combination, on transcription from the proximal 264 bp
PGC1𝛼-Luc minimal promoter, even though this contains
only a CRE and no PPRE [4], but transcription activities
and fold responses were 3–6-fold less compared with the
full length 2.6 kb PGC1𝛼-Luc (Figure 2(d)). Mutation of the
CRE on the 2.6 kb PGC1𝛼 promoter significantly decreased
both basal expression and the response to forskolin and
rosiglitazone, alone or in combination, by between 63% and
80% (𝑃 < 0.001), compared to wildtype 2.6 kb PGC1𝛼
(Figure 1(g)).
When reporter constructs under the control of promoters
containing repeats of either CRE (4 × CRE-Luc) or PPRE
(PPRE × 3-Luc) were examined, as expected, forskolin stim-
ulated mainly the CRE-Luc and rosiglitazone stimulated the
PPRE-Luc (𝑃 < 0.001; Figures 2(e) and 2(f)). However, there
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Figure 2: Luciferase reporter assay showing the effect of forskolin and rosiglitazone on (a) 3.1 kbpUCP1-Luc, (b) 260 bpUCP1-Luc, (c) 2.6 kbp
PGC1𝛼-Luc, (d) 264 bp PGC1𝛼-Luc, (e) CRE-mut 2.6 kbp PGC1𝛼-Luc, (f) 4 × CRE-Luc, and (g) 3 × PPRE-Luc, promoter activities. HIB-1B
cells were grown to confluence and then transiently transfected with the above -pGL3-Luc reporter construct, as indicated. Twenty-four hours
later, cells were treated with DMSO (control), rosiglitazone (10𝜇M) for 24 hours, or forskolin (10𝜇M) for the final 12 hours of rosiglitazone
treatment, in serum-free medium, before luciferase activity was measured. Values were expressed as fold increase of ratio of firefly to renilla.
Error barmeans themean± sem. of three observationswithin a single experiment performed in triplicate. ∗∗∗ Significant difference𝑃 < 0.001,
respectively, with respect to control; ### significant difference 𝑃 < 0.001 from wildtype due to the mutation of CRE.
6 PPAR Research
was significant stimulation of the PPRE-Luc by forskolin
(𝑃 < 0.001), of the CRE-Luc by rosiglitazone (𝑃 <
0.001), and a synergistic response to combined forskolin plus
rosiglitazone for both the CRE-Luc and PPRE-Luc (𝑃 <
0.001; Figures 2(e) and 2(f)). These results clearly suggest
that the synergistic response in the UCP1 promoter activity
to combined forskolin and rosiglitazone involves interaction
between pathways targeting the CREs and PPREs on the
UCP1 promoter.
4. Discussion
Expression of UCP1 in brown adipocytes can be induced in
vitro and in vivo by drugs that activate PKA and PPAR𝛾,
but few studies have examined the interaction between these
pathways. This study compares the expression of a number
of brown adipogenic genes in response to PKA and PPAR𝛾
stimulators and inhibitors in brown HIB-1B preadipocytes
and demonstrates that the synergistic induction of UCP1
expression by combined PKA activation and PPAR𝛾 agonist
treatment involves cross-talk between these pathways. This
conclusion is based on the abilities of a PKA inhibitor to
suppress responses to the PPAR𝛾 agonist and inhibition of
PKA stimulation by a PPAR𝛾 antagonist. The responses of
other brown adipogenic genes (Cidea, aP2) and regulators
of brown adipogenesis (PGC1𝛼, PRDM16, PPAR𝛾 C/EBP𝛽)
to PKA or PPAR𝛾 activation/inhibition were different from
UCP1, and, combined with reporter studies, we provide
evidence that these responses to PKA activation and the
PPAR𝛾 agonist treatment are targeted at the UCP1 pro-
moter.
Combined addition of forskolin plus rosiglitazone
resulted in a robust synergistic induction of UCP1 mRNA
expression in undifferentiated confluent HIB-1B cells.
A previous study was able to demonstrate a synergistic
response in UCP1 and PGC1𝛼 expression to acute (2 hours)
noradrenaline and chronic (continuously in the culture
medium) rosiglitazone in differentiated mouse primary
brown adipocytes [12]. Our luciferase reporter studies
demonstrated that this synergistic response required the
full length 3.1 kbp UCP1 promoter containing both the
enhancer and proximal promoter elements since a reporter
construct containing only the proximal 260 bp promoter was
nearly 10-fold less responsive, and stimulation by forskolin
+ rosiglitazone was only additive. The stimulatory effect of
rosiglitazone on the proximal UCP1 promoter was greater
than forskolin despite this construct containing only a
CRE and no PPRE. The ability of rosiglitazone to stimulate
transcription at CREs was confirmed using an artificial
promoter reporter containing tandem CRE repeats, as well
as a 264 bp PGC1𝛼 proximal promoter reporter, neither of
which contain a PPRE. Furthermore, when the CRE on the
PGC1𝛼 2.6 kbp promoter was mutated, there was a marked
diminution of the responses both to rosiglitazone alone and
combined forskolin + rosiglitazone. A previous study [13]
using a reporter construct containing the 220 bp enhancer
linked to a 73 bp minimal UCP1 promoter reporter construct
similarly observed synergistic activation by combined
PPAR𝛾 agonist and dibutyryl cAMP, but no responses were
observed with the 73 bp minimal promoter which does not
contain a CRE. Furthermore, the increase in UCP1 mRNA
expression by rosiglitazone treatment was abolished by
the PKA inhibitor, H89, and this effect was greatest when
forskolin was added in combination. This inhibitory effect
of H89 on gene expression in response to rosiglitazone
appeared to be greatest for UCP1 and was not observed
to the same extent with other genes involved in brown
adipogenesis (Cidea, PRDM16, C/EBP𝛽, and PGC1𝛼). The
evidence therefore suggests that rosiglitazone-stimulated
UCP1 expression, which is synergistically increased by
forskolin, is at least partly due to increased activation of the
CREs.
The mechanism by which rosiglitazone is able to stim-
ulate the PKA pathway is not known. Rosiglitazone is a
PPAR𝛾 ligand which increases the interaction of PPAR𝛾with
coactivators such as steroid receptor coactivator-1 (SRC-1)
and p300/CBP (CREB binding protein) containing histone
acetyl transferase activity, which is important for remodelling
chromatin to increase the transcriptional activity of nuclear
receptors [14]. GW9662 blocks the recruitment of these
coactivators [14], and therefore the stimulatory effect of
rosiglitazone on transactivation at the CRE may be caused
by chromatin remodelling. In the present study, rosiglitazone
strongly stimulated an artificial reporter containing tandem
PPREs and in the study of [13], mutation of the PPRE on the
UCP1 enhancer abolished responses to both PKA activation
and a PPAR𝛾 agonist. However, there has been a report in
primary brown adipocytes that rosiglitazone stimulates p38
MAPK phosphorylation in a non-PPAR𝛾 manner [8] which
would explain why the expression of PGC1𝛼 appeared to be
induced by rosiglitazone even in the presence of GW9662
(Figure 1(b)). PKA-dependent stimulation of PGC1𝛼 expres-
sion has been shown to involve p38-MAPK-dependent
phosphorylation of ATF2 [6, 10]. Therefore, rosiglitazone
activation of p38 MAPK would be likely to increase ATF2
phosphorylation and stimulate transcription from the CREs
in the PGC1𝛼 promoter, as suggested for the effects of PKA
activation.
The ability of rosiglitazone to stimulate the PPRE-Luc
reporter activity was markedly stimulated by addition of
forskolin, suggesting that increasing PKA activity was able
to synergise with rosiglitazone by increasing transactivation
of the PPRE on the UCP1 and PGC1𝛼 promoters. This
proposal was supported by evidence that forskolin stim-
ulation of UCP1 mRNA expression was partly decreased
by addition of the PPAR𝛾 antagonist GW9662. Recently,
it has been demonstrated that 𝛽-adrenergic agonist stim-
ulation of UCP1 expression in HIB-1B cells is associated
with an increase in PGC1𝛼 and PPAR𝛾 binding to the
PPRE on the UCP1 enhancer [15]. PKA induced binding
of C/EBP𝛽 to the PPAR𝛾2 promoter during adipogenesis is
known to increase chromatin accessibility of transcription
factors to the promoter [16], emphasising the importance
of chromatin remodelling in transcriptional responses to
PKA stimulation. Further studies are required to establish
functional crosstalk between the pathways targeting the
CREs and PPREs on the UCP1 promoter, for example,
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knocking down PPAR𝛾 or C/EBP𝛽 expression to establish
if this blocks induction by forskolin or rosiglitazone, respec-
tively.
In the present study, forskolin stimulated PGC1𝛼 expres-
sion by activating PKA as indicated by the complete sup-
pression with H89, and the stimulatory effect of forskolin
was almost totally blocked when the CRE in the proximal
promoter reporter construct was mutated, in agreement
with previous reports [6, 7]. Forskolin also induced the
expression of PPAR𝛾 and C/EBP𝛽, in a PKA-dependent
manner which is consistent with their role as transcription
factors stimulating both UCP1 and PGC1𝛼 expression [4, 6, 7,
9]. C/EBP𝛽, which is enriched in BAT compared to WAT, is
sensitive to cold stimulation in BAT and forskolin treatment
in HIB-1B cells, has been proposed to play a key role in the
cAMP induction of UCP1 and PGC1𝛼 expression in a white
adipocyte cell line [4, 9]. Therefore, our data showing that
C/EBP𝛽 expression is cAMP dependent and blunted by H89
is in accordance with previous studies. C/EBP𝛽 and PRDM16
have been shown to form a transcriptional complex which
increases PGC1𝛼 and UCP1 expression [9]. However, the
pattern of expression responses of PGC1𝛼, C/EBP𝛽, PPAR𝛾,
and PRDM16 to combined PKA stimulation and PPAR𝛾
agonist/antagonist treatment was generally different from
responses in UCP1 expression, suggesting that changes in the
expression of these regulators were not major factors in the
control of UCP1 transcription. This notion was supported
by our time course studies demonstrating that forskolin
stimulated UCP1 expression in confluent undifferentiated
HIB-1B cells within 24 hours while changes in PGC1𝛼,
C/EBP𝛽, and PRDM16 expression were either delayed for 72
hours or absent (results not shown). The control of UCP1
expression has previously been dissociated from that of
PGC1𝛼 in 𝛽1/𝛽2/𝛽3-adrenoceptor knockout (𝛽-less) brown
adipocytes in primary culture [17]. Furthermore, in PGC1𝛼
depleted cells, the amounts of several brown fat-selective
genes are not affected [18] supporting a role for PGC1𝛼 as a
coactivator of PPAR𝛾 in response to cold but not for brown
adipose differentiation.
The synergistic effects of combined PPAR𝛾 agonist and
PKA stimulation on UCP1 expression appear to be physi-
ologically relevant as surgical denervation of BAT pads in
rats prevented maximal brown adipogenic gene expression
in response to chronic rosiglitazone treatment [19]. Fur-
thermore, PPAR𝛾 ligand treatment can increase UCP1 and
PGC1𝛼 expression in rodent white adipose depots [20] or
preadipocytes fromWAT in mice [21] and humans [22].
5. Conclusions
The synergistic stimulation of UCP1 expression by combined
forskolin and rosiglitazone appears to be directly targeting
the UCP1 promoter and involves cross-talk between their
PKA and PPAR𝛾 signalling systems. This study suggests
that treating obesity by increasing energy expenditure as a
result of brown adipose thermogenesis is more likely to be
successful by combined drug therapy aimed at stimulating
both PKA and PPAR𝛾 signalling pathways.
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